MoonLake Immunotherapeutics (MLTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Zug, 스위스. 현재 CEO는 Jorge Santos da Silva.
MLTX 을(를) 보유 IPO 날짜 2020-10-20, 100 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $1.35B.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
